Acute Respiratory Distress Syndrome News and Research

RSS

New device combined with mechanical ventilation can help improve treatment outcomes for COVID-19

A device designed at the University of Pittsburgh could help improve outcomes as a treatment for COVID-19 when used in conjunction with non-invasive or mechanical ventilation, and it recently received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.

28 Apr 2020

COVID-19 can trigger serious inflammatory-related cardiovascular problems

The coronavirus disease (COVID-19) is potentially fatal for vulnerable populations like seniors who over 60 years old, and those with underlying medical conditions, like heart disease, diabetes, and lung disease. Reports show that patients are suffering from heart impairment caused by COVID-19. A new study sheds light on the effect of the novel coronavirus on the heart, causing cardiovascular problems, even in those without underlying heart conditions.

27 Apr 2020

Mapping complex peripheral immune response to severe COVID-19

In a recent article publicly available at medRxiv, researchers from Stanford have presented a single-cell atlas of the peripheral immune response to coronavirus disease (COVID-19), highlighting pertinent immunological features associated with the severe forms of the disease.

26 Apr 2020

Early Heparin therapy improves hypoxia in COVID-19 patients

The systemic use of heparin for treating severe coronavirus disease (COVID-19) showed significant improvements in oxygen exchange and overall clinical presentation of patients, as reported by a study from Brazil available on a preprint server medRxiv.

26 Apr 2020

New report highlights blood clot dangers in patients with COVID-19

A special report published today in the journal Radiology outlines prevention, diagnosis and treatment of complications stemming from blood clots in patients with COVID-19. The journal also published two research letters and a case study on this topic.

23 Apr 2020

RAS inhibitors and COVID-19 severity in hypertensive patients

A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.

23 Apr 2020

New research may shed light on people's susceptibility to COVID-19

Acute Respiratory Distress Syndrome in patients with COVID-19 can lead to death but more than 50% of these cases are associated with co-infection with bacterial pathogens.

23 Apr 2020

ACE2-TMPRSS2 profiling indicates tissue vulnerability to SARS-CoV-2 infection

A new study published in April 2020 on the preprint server bioRxiv reports that the different levels of susceptibility of various organs to viral attack by the SARS-CoV-2 virus causing the huge pandemic of COVID-19 sweeping around the world can be predicted from the level of expression of two molecules, the ACE2 receptor, and the TMPRSS2 protein.

20 Apr 2020

COVID-19 lung injury is not like high altitude pulmonary edema

A group of researchers with experience in treating high altitude pulmonary edema have written to correct the misconception in medical social media forums and elsewhere that the lung injury seen in COVID-19 is not like typical acute respiratory distress syndrome and is instead like HAPE.

20 Apr 2020

Penn Medicine launches convalescent plasma therapy trial for COVID-19 patients

Convalescent plasma therapy for COVID-19 patients -- an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection -- is the focus of a new two-part research initiative at Penn Medicine.

20 Apr 2020

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

A team of scientists at the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health, has tested the efficacy of remdesivir, a nucleotide analog prodrug with a broad antiviral activity, as a COVID-19 treatment.

20 Apr 2020

How are the interventions against COVID-19 working in Sweden?

In a new study, Swedish researchers speculate the effects of the present intervention strategies on the healthcare system as the COVID-19 pandemic affects the nation. Their study titled, “Intervention strategies against COVID-19 and their estimated impact on Swedish healthcare capacity,” has not been published yet; however, the findings are available as pre-peer-reviewed study at medRxiv.

19 Apr 2020

Hydroxychloroquine and azithromycin treatment in 80 COVID-19 patients: short-term outcomes

The COVID-19 pandemic is still spreading around the world and affecting nearly 2.4 million people, with over 164,000 dead so far. With neither vaccine nor proven therapeutic drug being available so far, the need of the hour is for effective treatment. Now, a new study reports the potential usefulness of a combination of hydroxychloroquine and azithromycin as a treatment in mild cases of COVID-19 infection and urges the need for further evaluation and widespread use if its findings are confirmed.

19 Apr 2020

Gimsilumab trial starts in first US patient with ARDS and COVID-19

The first American patient with COVID-19 and acute respiratory distress syndrome (ARDS) has been put on the drug gimsilumab at Temple University Hospital, as part of the BREATHE clinical trial. The trial, sponsored by Roivant Sciences, will evaluate the effectiveness of intravenous gimsilumab in preventing death in patients with COVID-19 and ARDS.

16 Apr 2020

Are overactive immune cells causing COVID-19-related deaths?

While the COVID-19 pandemic is devastating many regions, the world over, a new paper published in the Journal of Experimental Medicine in April 2020 describes the possibility that the critical or very severe cases of COVID-19 are due to the production of neutrophil extracellular traps (NET) due to hyperactivated immune cells.

16 Apr 2020

Octapharma USA supports new COVID-19 clinical trial

Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, M.D. of Sharp Memorial Hospital in San Diego, California focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator dependent.

16 Apr 2020

Regular exercise may reduce risk of deadly complication in patients with COVID-19

Regular exercise may reduce the risk of acute respiratory distress syndrome, a major cause of death in patients with the COVID-19 virus, a top exercise researcher reports.

15 Apr 2020

Hypertensive patients on ACE inhibitors and angiotensin receptor blockers may have improved COVID-19 prognosis

Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.

9 Apr 2020

What does recovery from COVID-19 look like? It depends. A pulmonologist explains.

Reports of recovery from serious illness caused by the coronavirus have been trickling in from around the world.

9 Apr 2020

Novel coronavirus targets specific secretory cells in the lungs

Viruses attack specific host cells, which can cause chaos in the body. The novel coronavirus, now called severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 for short, infects respiratory epithelial cells in the lining of the lung, causing difficulty of breathing. The usual cause of death of those who contract the virus is pneumonia and acute respiratory distress syndrome (ARDS). Now, a new study has found that SARS-CoV-2 specifically attack certain progenitor cells called bronchial transient secretory cells in the lungs.

9 Apr 2020